Trial · NCT01214655
Results by group63
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 63
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Recommended Dose and Schedule for Phase 2 Studies in Acute Leukemia | LY2523355 | 5 | mg/m^2/day; Days 1, 2, and 3 | ||
| Number of Participants With Clinically Significant Effects | Schedule A LY2523355 | 7 | Participants | ||
| Number of Participants With Clinically Significant Effects | Schedule B LY2523355 | 9 | Participants | ||
| Number of Participants With Clinically Significant Effects | Schedule C LY2523355 | 4 | Participants | ||
| Pharmacokinetics, Maximum Plasma Concentration (Cmax), Single Dose | Schedule A 2 mg LY2523355 | 198 | Geometric Coefficient of Variation 1410 | nanograms per milliliter (ng/mL) | |
| Pharmacokinetics, Maximum Plasma Concentration (Cmax), Single Dose | Schedule A 4 mg LY2524455 | 895 | Geometric Coefficient of Variation NA | nanograms per milliliter (ng/mL) | |
| Pharmacokinetics, Maximum Plasma Concentration (Cmax), Single Dose | Schedule A,C 5 mg LY2523355 | 240 | Geometric Coefficient of Variation 420 | nanograms per milliliter (ng/mL) | |
| Pharmacokinetics, Maximum Plasma Concentration (Cmax), Single Dose | Schedule A 6 mg LY2523355 | 391 | Geometric Coefficient of Variation 254 | nanograms per milliliter (ng/mL) | |
| Pharmacokinetics, Maximum Plasma Concentration (Cmax), Single Dose | Schedule B 8 mg LY2523355 | 169 | Geometric Coefficient of Variation 47 | nanograms per milliliter (ng/mL) | |
| Pharmacokinetics, Maximum Plasma Concentration (Cmax), Single Dose | Schedule B 10 mg LY2523355 | 354 | Geometric Coefficient of Variation 66 | nanograms per milliliter (ng/mL) | |
| Pharmacokinetics, Maximum Plasma Concentration (Cmax), Single Dose | Schedule B 12 mg LY2523355 | 254 | Geometric Coefficient of Variation 18 | nanograms per milliliter (ng/mL) | |
| Pharmacokinetics, Maximum Plasma Concentration (Cmax), Single Dose | Schedule B 14 mg 2523355 | NA | Geometric Coefficient of Variation NA | nanograms per milliliter (ng/mL) | |
| Pharmacokinetics, Maximum Plasma Concentration (Cmax), Single Dose | Schedule B 16 mg LY2523355 | 17,000 | Geometric Coefficient of Variation NA | nanograms per milliliter (ng/mL) | |
| Pharmacokinetics, Maximum Plasma Concentration (Cmax), Multiple Dose | Schedule A Day 3 2 mg LY2523355 | 43.1 | Geometric Coefficient of Variation 46 | nanograms per milliliter (ng/mL) | |
| Pharmacokinetics, Maximum Plasma Concentration (Cmax), Multiple Dose | Schedule A Day 3 4 mg LY2523355 | 2440 | Geometric Coefficient of Variation NA | nanograms per milliliter (ng/mL) | |
| Pharmacokinetics, Maximum Plasma Concentration (Cmax), Multiple Dose | Schedule A/C Day 3 5 mg LY2523355 | 439 | Geometric Coefficient of Variation 391 | nanograms per milliliter (ng/mL) | |
| Pharmacokinetics, Maximum Plasma Concentration (Cmax), Multiple Dose | Schedule A Day 3 6 mg LY2523355 | 187 | Geometric Coefficient of Variation 69 | nanograms per milliliter (ng/mL) | |
| Pharmacokinetics, Maximum Plasma Concentration (Cmax), Multiple Dose | Schedule B Day 9 8 mg LY2523355 | 155 | Geometric Coefficient of Variation 139 | nanograms per milliliter (ng/mL) | |
| Pharmacokinetics, Maximum Plasma Concentration (Cmax), Multiple Dose | Schedule B Day 9 10 mg LY2523355 | 283 | Geometric Coefficient of Variation 23 | nanograms per milliliter (ng/mL) | |
| Pharmacokinetics, Maximum Plasma Concentration (Cmax), Multiple Dose | Schedule B Day 9 12 mg LY2523355 | NA | Geometric Coefficient of Variation NA | nanograms per milliliter (ng/mL) |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01214655/results